ArticleFrontiers in oncology2026
Down-regulation of THBS2 inhibits the malignant progression of Burkitt lymphoma by blocking the PI3K/AKT/c-MYC pathway.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thrombospondin 2 (THBS2) is overexpressed in various solid tumors and is a prognostic gene of Burkitt lymphoma (BL), but its role and molecular mechanism in BL still need to be explored. Methods: Western blot (WB) detected the protein expression of THBS2 in BL cells. si-THBS2 was transfected into CA46 and RAJI cells to detect cell malignant phenotype and cell cycle changes. WB detected the protein expression of epithelial-mesenchymal transition (EMT), apoptosis, cell cycle and the PI3K/AKT/c-MYC pathway proteins. ChIP-qPCR detected the binding ability of MYC to target gene promoters, and Co-IP detected the level of MYC/MAX dimerization. Tumor stem cell sphere formation assays evaluated cell stemness changes. The subcutaneous xenograft model of RAJI cells was developed to observe the effect of THBS2 knockdown on tumor growth. Results: THBS2 protein was markedly up-regulated in BL cells. Knockdown of THBS2 could inhibit the growth and EMT process, inhibit the protein levels of cyclins (CDK2, CDK4, CDK6 and CyclinD1), inhibit the sphere formation ability of stem cells and down-regulate SOX2 and OCT4 expressions. THBS2 knockdown inhibited the PI3K/AKT pathway phosphorylation, declined c-MYC expressions, weakened the MYC/MAX dimerization and the binding ability of MYC to target gene promoters. In addition, THBS2 knockdown also significantly inhibited the growth of subcutaneous xenografts of RAJI cells, reduced the positive rates of Ki67 and PCNA, declined the protein levels of cyclins, and inhibited the PI3K/AKT/c-MYC pathway. Overexpression of c-MYC or 740Y-P treatment partially reversed the tumor malignant phenotype inhibition caused by THBS2 knockdown and partially restored cyclin levels. Conclusion: Knockdown of THBS2 inhibited the malignant phenotype, EMT and stem cell-like characteristics via inhibiting the PI3K/AKT/c-MYC signaling axis, and blocked the cell cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.